Nucala FDA Approval History
FDA Approved: Yes (First approved November 4, 2015)
Brand name: Nucala
Generic name: mepolizumab
Dosage form: Injection
Treatment for: Asthma, Eosinophilic Granulomatosis with Polyangiitis, Hypereosinophilic Syndrome
Nucala (mepolizumab) is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for the add-on maintenance treatment of patients ≥6 years with severe eosinophilic asthma, for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), and for the treatment of patients ≥12 years with hypereosinophilic syndrome (HES).
Development Timeline for Nucala
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.